Company Profile

Adipo Therapeutics LLC
Profile last edited on: 10/16/19      CAGE: 7RX63      UEI: H3ZMV3VXHPP7

Business Identifier: Potential therapeutic treatment of obesity
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3630 Swansea Drive
West Lafayette, IN 47906
   (434) 409-9135
Location: Single
Congr. District: 04
County: Tippecanoe

Public Profile

Founded by a Purdue University assistant professor and anassociate, Adipo Therapeutics is developing a disruptive technology platform involving use of polymer-based nanoparticulate drug delivery systems to induce adipocyte browning as a safe and effective therapeutic solution to treat obesity. Adipocyte browning is usefully understood as converting energy-storing bad fat cells into energy-burning good fat cells in the body. The innovation combines the recent discovery of the role played by Notch signaling in adipocyte plasticity with advances in polymer-based drug delivery. This technology offers several unique value propositions including sustainable weight loss, improved glucose homeostasis and systemic metabolism - all with minimal off-target side effects. Such an enabling technology platform also has the potential for ready adaption to treat a broad spectrum of diseases such as fatty liver disease and atherosclerosis

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2018 1 NIH $198,323
Project Title: Polymeric Nanoparticles for Inductive Browning of White Adipose Tissue

Key People / Management

  Meng Deng -- Founder

  Shihuan Kuang